Sandoz Group AG (SDZNY)
Market Cap | 17.36B |
Revenue (ttm) | 10.38B |
Net Income (ttm) | n/a |
Shares Out | n/a |
EPS (ttm) | n/a |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | 0.53 (1.33%) |
Ex-Dividend Date | Apr 22, 2025 |
Volume | 3,124 |
Average Volume | 50,971 |
Open | 39.99 |
Previous Close | 39.72 |
Day's Range | 40.02 - 40.65 |
52-Week Range | 32.48 - 49.81 |
Beta | n/a |
RSI | 46.23 |
Earnings Date | Aug 7, 2025 |
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. The company covers therapeutic areas, including cardiovascular, central nervous system, oncology, infectious diseases, pain and respiratory, diabetes, immunology, endocrinology, hematology, and ophthalmology. It also provides a portfolio of active pharmaceutical ingredients and finished dosage forms. The company was founded in 1886 and is headquartered in Basel, Switzerland. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews

Shareholders approve all resolutions proposed by Board of Directors at Annual General Meeting of Sandoz Group AG
Basel, April 15, 2025 – Sandoz (SIX:SDZ;OTCQX:SDZNY) today announced that its shareholders approved all proposals of the Board of Directors at its Annual General Meeting, including the Annual Financia...

Sandoz Files Lawsuit Alleging Amgen Illegally Blocked Biosimilar Competition For Its Blockbuster Arthritis Drug
Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) on Monday filed an antitrust lawsuit in the U.S. against Amgen, Inc. (NASDAQ: AMGN) for extending and entrenching the dominant market position of its block...

[Corrected] Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules – corrected: reference to date of product launch in Europe removed; link to “Important Safety Information” updated
Amgen faces antitrust lawsuit from Sandoz over Enbrel patents
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept ...
Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US | SDZNY Stock News

Switzerland's Sandoz files antitrust lawsuit against Amgen in US
Swiss generic drug manufacturer Sandoz said on Monday it had filed an antitrust lawsuit in the U.S. against Amgen for entrenching the dominant market position of its blockbuster medicine, Enbrel (etan...

Sandoz files antitrust litigation against Amgen regarding patient access to etanercept biosimilar in the US
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Company aims to accelerate access to much-needed biosimilar to reference medicine Enbrel®* for US patients with disabling infla...
Novartis After Sandoz: The Business Without Generics

Competencia investiga a Sandoz, Alliance Healthcare España y Bluetab Solutions
La Comisión Nacional de los Mercados y la Competencia (CNMC) sigue tirando del hilo abierto en diciembre de 2023 sobre el funcionamiento ...

Sandoz strengthens its balance sheet by issuing new bonds to repay spin-off term loans, and signs new USD 2 billion revolving credit facility
New USD 2.0 billion multi-currency revolving credit facility (RCF) in place to further strengthen Sandoz balance sheet and liquidity. New facility replaces initial and unutilized USD 1.25 billion RCF,...
Sandoz: Upgrading To A Buy On 2028 Expectations

Sandoz signs landmark supply and manufacturing agreement
BOUCHERVILLE, Quebec, March 18, 2025 (GLOBE NEWSWIRE) -- Sandoz Canada, the leader in generic and biosimilar medicines in Canada, has signed a 10-year, long-term supply agreement with its partner Delp...
Thanks to $60 Million Federal Investment - DELPHARM TO MODERNIZE ITS FACILITIES AND ENSURE CONTINUED PRODUCTION OF STERILE INJECTABLE MEDICINES IN BOUCHERVILLE
BOUCHERVILLE, QC , March 18, 2025 /CNW/ - Delpharm, a world leader in pharmaceutical outsourcing, announced that it has reached an agreement with the Government of Canada to modernize its injectable m...
Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth ...
Sandoz Group AG (SDZNY) (Q4 2024) Earnings Call Highlights: Record Sales and Strategic Growth Initiatives
US Tariffs Will Raise Drug Prices for Patients, Sandoz CEO Says
The US shift toward steep tariffs will likely make drugs more expensive and limit access for patients, according to one of the world’s largest makers of generic medicines.
Health Care Roundup: Market Talk
Find insight on Bayer, Sandoz, Fresenius and more in the latest Market Talks covering Health Care.
Sandoz Group AG Non-GAAP EPS of $2.71, revenue of $10.36B; initiates FY25 outlook

Sandoz reports strong FY 2024 results and Q4 2024 sales
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE FY 2024 net sales[1] of USD 10.4 billion, up by 9%[2] in constant currencies (+7% in USD); Q4 net sales of USD 2....

Avecho and Sandoz enter exclusive license and development agreement to commercialise CBD for insomnia in Australia
Highlights: Avecho and Sandoz sign an exclusive ten-year development and license agreement ("Agreement") for Avecho's pharmaceutical cannabidiol capsule for insomnia in Australia Avecho to receive upf...

Sandoz family foundation offers $3 billion worth of Novartis shares
Emasan AG, an arm of the Sandoz Family Foundation, has launched a public offering of some 26.5 million shares in Swiss pharmaceutical firm Novartis to raise up to $3 billion in an accelerated bookbuil...

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
A cost-saving effort by NHS England to transition multiple sclerosis (MS) patients from Biogen Inc’s (NASDAQ: BIIB) Tysabri (natalizumab) to the biosimilar drug Tyruko has led to significant side eff...
Sandoz launches biosimilar Pyzchiva in U.S. for all approved Stelara indications

MS patients suffer side-effects after NHS England switches to cheaper drug
Scores of people experience complications after change from Tysabri to Tyruko as part of NHS drive to save money ‘It was awful for me’: one MS patient shares her experience with Tyruko Scores of peopl...

Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules Key biosimilar value driver contributes to Sandoz global growth strategy and moves company closer to becoming #1 in biosimilars...

Francisco Ballester to retire; Peter Stenico appointed President Region International
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of service Peter Stenico, cu...